INSMED (IM8N BE) stock market data APIs
€146.9492
0(0%)
as of December 22, 2025
Try our APIs with
free plan!
INSMED Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for IM8N.BE.
Prev. Close
146.9492
Open
146.9492
High
146.9492
Low
146.9492
52 wk Range
55-180
Market Cap
2 766 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get INSMED data using free add-ons & libraries
Get INSMED Fundamental Data
INSMED Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
INSMED News
New
US Stock Market Today: S&P 500 Futures Rise amid Global Rate Hikes, Cooling Inflation
The Morning Bull - US Market Morning Update Friday, Dec, 19 2025 US stock futures are pointing higher this morning, with benchmark contracts up about 0.3 percent, as investors weigh two big global si...
These Stocks Moved the Most Today: Micron, DJT, Accenture, Tilray, Lululemon, Medline, Rivian, and More
Shares in memory-chip makers Micron and Sandisk rally after Micron tops Wall Street's earnings estimates. Continue Reading
Insmed's Pipeline Can Deliver Potential Gains Despite Brensocatib Setback, RBC Says
Insmed's (INSM) termination of its clinical trial evaluating brensocatib in patients with chronic rh PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset
Shares of Insmed INSM lost nearly 20% in after-market trading on Wednesday after the company announced the failure of a mid-stage study evaluating Brinsupri (brensocatib) in chronic rhinosinusitis wit...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
